Sold as Tz-3, Vagistat-1. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 13, 2026, FDA lists 3 applications for Tioconazole (sold as Tz-3, Vagistat-1), first approved Feb 18, 1983, with 0 new uses approved and 0 published complete response letters.
| Feb 18, 1983 | Tz-3NDA 18682 · New molecular entity | Pfizer | 2 | Discontinued |
| Feb 11, 1997 | Vagistat-1NDA 20676 · TYPE 8 | Combe | 7 | Marketed |
| Nov 21, 2001 | TioconazoleANDA 75915 | Perrigo | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer
Perrigo